< Back to search
Filter
1
FeaturedActive & Responsive

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

for
Metastatic Breast Cancer
Location: Durham NC, Chattanooga TN, Nashville TN, Germantown TN,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT03424005

Phase1, Phase2, Recruiting
Featured

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

for
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer,
Location: Boston MA, Philadelphia PA, Charlotte NC, Germantown TN,
Sponsor: Hoffmann-La Roche

Sex: Female

Age: 18+

Code: NCT04802759

Phase1, Phase2, Recruiting
Featured

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

for
Metastatic Breast Cancer
Location: Moncton, Boston MA, Quebec, Montreal, Hyattsville MD,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT05894239

Phase3, Recruiting
Featured

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

for
Early Breast Cancer
Location: Sterling Heights MI, Fountain Valley CA
Sponsor: Genentech, Inc.

Sex: Female

Age: 18+

Code: NCT07541079

Phase3, Recruiting
Featured

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

for
Breast Cancer
Location: East Brunswick NJ, Jacksonville FL, Kansas City MO,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07368998

Phase2, Recruiting

Interested in new breast cancer trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Featured

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

for
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma,
Location: San Antonio TX
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06084481

Phase1, Recruiting
Featured

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

for
HER2-positive Breast Cancer
Location: Shirley NY, Quebec, Albany NY, East Brunswick NJ,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07413939

Phase2, Phase3, Recruiting
Featured

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

for
Breast Cancer
Location: Boston MA, East Patchogue NY, The Bronx NY,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT07100106

Phase1, Phase2, Recruiting
Featured

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

for
Breast Cancer
Location: Montreal, Morgantown WV, Toronto, Germantown TN,
Sponsor: Hoffmann-La Roche

Sex: Female

Age: 18+

Code: NCT07054190

Phase2, Recruiting
Featured

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

for
Breast Cancer
Location: Chicoutimi, Montreal, Ottawa, Toronto, Jacksonville FL,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07405801

Phase2, Recruiting
Featured

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

for
Breast Cancer
Location: Moncton, The Bronx NY, New York NY, East Brunswick NJ,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06790693

Phase3, Recruiting
Featured

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

for
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer,
Location: Bensalem PA, Philadelphia PA, Annapolis MD, Raleigh NC,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06065748

Phase3, Recruiting
Active & Responsive

HER2 Vaccine for Locally Advanced Breast Cancer

for
Breast Cancer, HER2-positive Breast Cancer
Location: Indianapolis IN
Sponsor: Pravin T.P Kaumaya

Sex: All

Age: 18+

Code: NCT06949410

Phase1, Recruiting
Active & Responsive

HER-2 B Cell Peptide Vaccine

for
Metastatic Breast Cancer, HER2-positive Breast Cancer,
Location: Indianpolis IN
Sponsor: Pravin T.P Kaumaya

Sex: All

Age: 18+

Code: NCT06414733

Phase1, Recruiting
Active & Responsive

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

for
Breast Cancer
Location: Columbus OH, Chicago IL, Iowa City IA
Sponsor: University of Illinois at Chicago

Sex: All

Age: 18+

Code: NCT06169371

Recruiting
Active & Responsive

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Gloucester MA, Beverly MA, Peabody MA, Winchester MA,
Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05929768

Phase3, Recruiting
Active & Responsive

Community Services Navigation to Advance Health Equity in Breast Cancer Screening

for
Breast Cancer
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: All

Age: 18+

Code: NCT06305312

Recruiting
Active & Responsive

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

for
Cancer, Breast Cancer, Lung Cancer, Colon Cancer,
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT03702309

Recruiting
Active & Responsive

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

for
Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT06682793

Phase1, Phase2, Recruiting
Active & Responsive

A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients

for
Breast Cancer Screening, Artificial Intelligence (AI)
Location: Boston MA, Miami FL, Madison WI, Seattle WA,
Sponsor: Jonsson Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT06934239

Recruiting